$3.91 Earnings Per Share Expected for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) This Quarter

Brokerages forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) will report $3.91 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $3.87 and the highest estimate coming in at $3.94. Eagle Pharmaceuticals reported earnings of $0.24 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 1,529.2%. The business is expected to issue its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that Eagle Pharmaceuticals will report full year earnings of $10.86 per share for the current fiscal year, with EPS estimates ranging from $9.66 to $12.32. For the next year, analysts expect that the company will post earnings of $4.17 per share, with EPS estimates ranging from $2.88 to $5.46. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRXGet Rating) last issued its earnings results on Monday, March 7th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.41 by ($0.89). The business had revenue of $42.32 million for the quarter, compared to analyst estimates of $47.32 million. Eagle Pharmaceuticals had a negative return on equity of 4.62% and a negative net margin of 5.03%. During the same period last year, the company posted $0.60 earnings per share.

Several brokerages have weighed in on EGRX. StockNews.com began coverage on Eagle Pharmaceuticals in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $57.00 target price on the stock in a research report on Monday, March 14th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $54.00.

NASDAQ EGRX traded down $0.70 during trading hours on Wednesday, hitting $44.67. The company had a trading volume of 724 shares, compared to its average volume of 107,159. Eagle Pharmaceuticals has a fifty-two week low of $36.48 and a fifty-two week high of $58.25. The business has a fifty day simple moving average of $48.48 and a 200-day simple moving average of $49.19. The firm has a market cap of $567.31 million, a P/E ratio of -67.72 and a beta of 0.68.

Institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in Eagle Pharmaceuticals by 1.5% during the fourth quarter. California State Teachers Retirement System now owns 15,738 shares of the specialty pharmaceutical company’s stock worth $801,000 after acquiring an additional 234 shares during the period. Lazard Asset Management LLC boosted its position in Eagle Pharmaceuticals by 11.5% during the 4th quarter. Lazard Asset Management LLC now owns 2,405 shares of the specialty pharmaceutical company’s stock worth $122,000 after acquiring an additional 248 shares during the period. PNC Financial Services Group Inc. boosted its position in Eagle Pharmaceuticals by 36.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 1,144 shares of the specialty pharmaceutical company’s stock worth $63,000 after acquiring an additional 304 shares during the period. Parametric Portfolio Associates LLC boosted its position in Eagle Pharmaceuticals by 0.5% during the 4th quarter. Parametric Portfolio Associates LLC now owns 67,017 shares of the specialty pharmaceutical company’s stock worth $3,413,000 after acquiring an additional 327 shares during the period. Finally, Allianz Asset Management GmbH boosted its position in Eagle Pharmaceuticals by 6.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 6,046 shares of the specialty pharmaceutical company’s stock worth $337,000 after acquiring an additional 360 shares during the period. 88.71% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile (Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Read More

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.